[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100604826":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":30,"responsibleParty":47,"collaborators":49,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":10,"studyType":65,"phases":10,"briefSummary":66,"conditions":67,"keywords":72,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Yunnan Cancer Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"NIR-II probe incubation",null,"NIR-II probe incubation Group\u002FCohort Description: Freshly excised SLNs will be fully immersed in NIR-II probe ((i.e:ICG-CK) incubation solution (6.25, 12.5, 25, 50, 100 ug\u002FmL) for 1, 3, 5, 7, or 10 min, then rinsed with PBST buffer for 5 min and dried with absorbent paper. NIR-II fluorescence imaging will then be performed under the DPM NIR-II system. The correlation between pathological features and fluorescence information will be further analyzed.",[13],"Diagnostic Test: NIR-II probe (i.e ICG-CK) incubation solution",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DIAGNOSTIC_TEST","NIR-II probe (i.e ICG-CK) incubation solution","After incubating the lymph node tissue with an optimal concentration of NIR-II probe for an appropriate amount of time, the tissue is washed with eluent, and then the fluorescence intensity of different tissues is detected to assess whether the tissue has cancer tissue invasion.",[9],[21,26],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Junhong Chen, Postgraduate","CONTACT","86+17782287838","1145644908@qq.com",{"name":27,"role":23,"phone":28,"phoneExt":10,"email":29},"Weiling Chen, Doctor","86+13646039812","913208146@qq.com",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":10,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Yunnan Cancer Hospital, Kunming, Yunnan 650118","RECRUITING","Kunming","Yunnan","China","CN",{"type":39,"coordinates":40},"Point",[41,42],102.71833,25.03889,{"lat":42,"lon":41},[45],{"name":46,"role":23,"phone":24,"phoneExt":10,"email":25},"Junhon Chen, Postgraduate",{"type":48,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[50],{"name":51,"class":6},"Xiang'an Hospital of Xiamen University","100604826","rapid-assessment-of-sentinel-lymph-node-metastasis-status-using-a-pan-ck-targeting-nir-ii-fluorescent-probe-in-breast-cancer-100604826",false,"NCT07154563","Rapid Assessment of Sentinel Lymph Node Metastasis Status Using a Pan-CK-targeting NIR-II Fluorescent Probe in Breast Cancer","NIR-II","Inclusion Criteria:\n\n* Adult patients between 18-75 years of age\n* Patients presenting with a breast nodule or mass presumed to be resectable on pre-operative assessment\n* Breast cancer patients who are scheduled to undergo sentinel lymph node biopsy or axillary lymph node dissection;\n* Good operative candidate\n* Subject capable of giving informed consent and participating in the process of consent\n\nExclusion Criteria:\n\n* Patients unable to participate in the consent process\n* Patients had contraindications to surgery, such as serious cardiopulmonary disease, coagulation dysfunction, etc","FEMALE","18 Years","75 Years",{"count":63,"type":64},60,"ESTIMATED","OBSERVATIONAL","Breast malignant tumors are a serious threat to women's health, and the current treatment for breast malignant tumors is still dominated by surgery, but the problems faced by patients after surgery such as edema and tumor recurrence are still relatively common, and the high recurrence rate and the occurrence of postoperative complications are closely related to the removal of metastatic lymph nodes during surgery. Therefore, accurate assessment of sentinel lymph node (SLN) metastases is essential to determine the extent of axillary lymph node dissection (ALND) and minimize complications. In this study, we developed a new technique that can rapidly distinguish between metastatic lymph nodes and normal sentinel lymph nodes (SLNs) in breast cancer patients. Briefly, fresh tissue is incubated with the probe and imaged immediately after intraoperative sentinel lymph node resection to identify the metastatic status of SLN. The accuracy of fluorescence imaging is confirmed by pathological diagnosis.",[68,69,70,71],"Breast Cancer Metastatic","Sentinel Lymph Node","Sentinel Lymph Node Biopsy (SLNB)","Metastasis",[57,73,69,71],"Breast Cancer","2025-08-27",{"date":76,"type":77},"2025-09-04","ACTUAL",{"date":79,"type":77},"2025-02-01",{"date":81,"type":64},"2026-12-01",{"name":5,"class":6},1]